On Wednesday, DDR Corp (NYSE:DDR)’s shares inclined 0.30% to $16.47.
DDR Corp. (DDR) declared operating results for the second quarter ended June 30, 2015.
Financial Highlights
- Second quarter operating funds from operations attributable to common shareholders (“Operating FFO”) raised $10.1 million to $111.4 million, or $0.31 per diluted share, contrast to $101.3 million, or $0.28 per diluted share, for the preceding-year comparable period.
- Second quarter net income attributable to common shareholders was $13.0 million, or $0.03 per diluted share, which compares to net income of $67.8 million, or $0.19 per diluted share, for the preceding-year comparable period.
NoteworthyQuarterly Activity
- Generated same store net operating income growth of 3.0% on a pro rata basis.
- Executed 369 new leases and renewals for 2.9 million square feet.
- The annualized base rent per occupied square foot was $14.37 at June 30, 2015 as contrast to $13.72 at June 30, 2014, an enhance of 4.7% on a pro rata basis.
- Generated new leasing spreads of 25.4% on a pro rata basis, and renewal leasing spreads of 7.2% on a pro rata basis.
- The portfolio leased rate was 95.8% at June 30, 2015 and 2014 on a pro rata basis.
- Attained $111 million of wholly-owned prime power centers.
- Sold ten assets totaling $60 million at DDR’s share.
DDR Corp. is an equity real estate investment trust. It invests in the real estate markets of the United States and Puerto Rico. The firm is in the business of acquiring, owning, developing, redeveloping, expanding, leasing and managing shopping centers. It formerly known as Developers Diversified Realty Corp. DDR Corp is based in Beachwood, Ohio.
Level 3 Communications, Inc. (NYSE:LVLT)’s shares dropped -1.66% to $48.12.
Level 3 Communications, Inc. (LVLT) stated results for the second quarter 2015.
Total revenue was $2.061 billion for the second quarter 2015, contrast to $2.030 billion on a pro forma basis, for the second quarter 2014, assuming the telecom acquisition took place on January 1, 2014.
In the second quarter 2015, the company generated net income of $150 million and basic earnings per share of $0.42, which excludes a loss on the extinguishment and modification of debt, related to refinancing transactions accomplished during the quarter. That loss was about $163 million or $0.46 per share. Counting this loss, basic and diluted earnings per share were ($0.04). For the second quarter 2014, pro forma net income was $45 million and basic and diluted earnings per share were $0.13.
Level 3 Communications, Inc., together with its auxiliaries, operates as a facilities-based provider of a range of integrated communications services primarily in North America, Latin America, Europe, the Middle East, and Africa. The company provides transport services comprising wavelengths, private lines, transoceanic, and dark fiber, in addition to related professional services; fiber services; and colocation and data center services, such as cloud, hosting, and application administration solutions.
At the end of Wednesday’s trade, Inovio Pharmaceuticals Inc (NASDAQ:INO)‘s shares showed no change to $7.82.
Inovio Pharmaceuticals Inc (INO) declared that Inovio’s Chief Executive Officer, Dr. J. Joseph Kim, has been selected as the “Entrepreneur of the Year(TM)” for Greater Philadelphia by Ernst & Young, a global leader in assurance, tax, and advisory services.
Dr. Kim, who co-founded the organization that became Inovio Pharmaceuticals, was recognized for his vision, passion, medical and financial acumen in building Inovio from a two-person start-up into a clinical-stage publicly traded immunotherapy company with innovative therapies for cancers and infectious diseases.
Last year, Inovio stated a medical breakthrough by demonstrating the first clinically meaningful efficacy results from T cells generated exclusively in vivo in the history of its DNA based immunotherapy technology. These results were from a phase II study treating cervical pre-cancer. Early next year, Inovio will move this lead product into phase III. The company has also received more than $70 million in government grants in the past eight months to develop HIV, influenza and Ebola treatments and vaccines.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electro oration delivery devices to prevent and treat cancers and infectious diseases. The company’s SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Monsanto Company (NYSE:MON), ended its Wednesday’s trading session with 0.70% gain, and closed at $103.25.
The Climate Corporation, a division of Monsanto Company (MON), declared that farmers have mapped more than 75 million row crop acres in their digital agriculture platform, up from 50 million acres in 2014. This noteworthyacre adoption represents nearly 45 percent of all corn and soybean acres planted in the U.S. The company’s digital agriculture platform comprises Climate Basic™, Climate Pro™ and FieldView® from Precision Planting. The company also declared Climate Pro, their premium web and mobile product offering, has grown considerably from its initial launch from 1 million acres last year to more than 5 million acres this year across the U.S.
Together these tools provide one account with multiple product offerings and access points. The farmer can log in on a tablet from his tractor, on a mobile phone as he scouts his fields, or on his desktop computer.
The company emphasized the importance of farmer adoption to the future success of this emerging platform. “The interest we’ve seen from farmers this year in our digital platform reinforces the impact these tools ultimately can have on our industry,” said Mike Stern, President and Chief Operating Officer for The Climate Corporation. “We want to be the digital platform of choice for farmers, and our growth this year is evidence that we’re well on that path,” said Stern.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces row crop seeds, counting corn, soybean, cotton, and canola seeds principally under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds comprising of tomato, pepper, melon, cucumber, pumpkin, squash, beans, broccoli, onions, lettuce, and other seeds under the Seminis and De Ruiter brands.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
